How Often Is Tudorza Dosed?
Tudorza Pressair (aclidinium bromide) is used twice daily—in the morning and evening—for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. Each dose is one inhalation from the Pressair inhaler (400 mcg).[1]
Why Twice Daily Instead of Once?
Aclidinium has a shorter duration of action compared to some other long-acting muscarinic antagonists (LAMAs) like tiotropium (Spiriva), which is once daily. Clinical studies showed twice-daily dosing provides consistent 24-hour bronchodilation with peak effects within 5 minutes and sustained improvement in lung function over 12 hours per dose.[1][2]
What Happens If You Miss a Dose?
Take the missed dose as soon as you remember, then resume your regular twice-daily schedule. Do not double up doses. Spacing doses about 12 hours apart helps maintain steady drug levels.[1]
Common Side Effects Patients Report
Twice-daily use links to side effects like headache (6%), nasopharyngitis (5%), cough (3%), and paradoxical bronchospasm (1%). Anticholinergic effects such as dry mouth or urinary retention occur in under 3% of users. Rinse your mouth after inhaling to reduce irritation.[1][2]
How Does Tudorza Compare to Once-Daily COPD Inhalers?
| Inhaler | Dosing | Active Ingredient | Key Difference |
|---------|--------|-------------------|---------------|
| Tudorza Pressair | Twice daily | Aclidinium | Fixed-dose LAMA; breath-actuated inhaler |
| Spiriva Respimat | Once daily | Tiotropium | Longer half-life; more flexible timing |
| Incruse Ellipta | Once daily | Umeclidinium | Similar efficacy; often combined with LABAs |
| Seebri Breezhaler | Twice daily | Glycopyrrolate | Comparable profile to Tudorza |
Tudorza matches efficacy of once-daily options in trials but requires stricter adherence.[2]
Who Makes Tudorza and When Do Patents Expire?
Takeda Pharmaceuticals markets Tudorza in the US. Key US patents (e.g., 8,110,452 for formulation) expire around 2025-2028, with some pediatric exclusivity extensions. Generic challenges are ongoing; check DrugPatentWatch.com for latest litigation and Paragraph IV filings.[3]
[1]: Tudorza Pressair Prescribing Information, AstraZeneca, 2023. https://www.tudorza.com
[2]: GOLD 2023 COPD Guidelines, Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org
[3]: DrugPatentWatch.com, Aclidinium Bromide Patents. https://www.drugpatentwatch.com/p/tradename/TUDORZA+PRESSAIR